Literature DB >> 7584093

Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors.

M J Wood1, A P Byrnes, D W Pfaff, S D Rabkin, H M Charlton.   

Abstract

The use of viral vectors which infect and express genes in post-mitotic neurons is a potential strategy for the treatment of disorders affecting the central nervous system (CNS). However, the inflammatory consequences of such strategies have yet to be systematically examined. Preparations of non-replicating defective herpes simplex virus type 1 (HSV-1) amplicon vectors containing the lacZ gene were obtained by standard methods and stereotaxically injected into the adult rat dentate gyrus (DG). The consequent gene expression and inflammatory effects following microinjection were investigated. beta-Galactosidase activity was detected in neurons of the DG from 24 h to at least 12 days after vector injection. A strong inflammatory response developed within 2 days, characterized by diffuse up-regulation of major histocompatibility complex (MHC) class I antigens and the activation of microglia. After 4 days the recruitment of MHC class II+ cells, activated T lymphocytes and macrophages was detected. These features persisted for at least 31 days. Of importance was the finding of beta-galactosidase activity in a bilateral group of neurons in the supramammillary nuclei (SMN) of the posterior hypothalamus, known to send afferent projections to the DG. The onset of inflammation at this secondary site was delayed, but its cellular characteristics resembled those found at the primary site of injection. Thus, the use of preparations of defective HSV-1 vectors for gene transfer in the CNS has immunological implications both at primary and secondary sites within the CNS.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584093

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 2.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

Review 3.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 4.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 5.  Immune responses to herpesviral vectors.

Authors:  Deborah A Ryan; Howard J Federoff
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

Review 6.  Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

7.  Modulation of rat rotational behavior by direct gene transfer of constitutively active protein kinase C into nigrostriatal neurons.

Authors:  S Song; Y Wang; S Y Bak; M J During; J Bryan; O Ashe; D B Ullrey; L E Trask; F D Grant; K L O'Malley; H Riedel; D S Goldstein; K A Neve; G J LaHoste; J F Marshall; J W Haycock; R L Neve; A I Geller
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

8.  Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

Authors:  Mei Sun; Lingxin Kong; Xiaodan Wang; Xiu-gui Lu; Qingsheng Gao; Alfred I Geller
Journal:  Brain Res       Date:  2005-08-09       Impact factor: 3.252

9.  Improved long-term expression from helper virus-free HSV-1 vectors packaged using combinations of mutated HSV-1 proteins that include the UL13 protein kinase and specific components of the VP16 transcriptional complex.

Authors:  Meng Liu; Xiaodan Wang; Alfred I Geller
Journal:  BMC Mol Biol       Date:  2009-06-16       Impact factor: 2.946

10.  Herpes Virus Amplicon Vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.